Mallinckrodt Ends Enrollment in Phase III for Terlipressin

Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.

More Headlines

Follow worldbiztoday on Twitter

US Stocks